The effects of reboxetine on autonomic and cognitive functions in healthy volunteers

Naga Chalasani, W. Scott Clark, L. G. Martin, Jeffrie Kamean, M. Abdul Khan, Nilesh H. Patel, Thomas D Boyer

Research output: Contribution to journalArticle

36 Citations (Scopus)

Abstract

Rationale: Though reboxetine, a selective nor-adrenaline reuptake inhibitor, causes autonomic and cognitive adverse events there is a paucity of appropriately designed studies on the cognitive and autonomic effects of the drug in the literature. Objective: To compare the effects of reboxetine on cognitive and autonomic functions with those of placebo in healthy humans. Method: A randomised, double-blind, crossover study of 12 healthy male volunteers aged 25 (21-27; median, range) years. Subjects orally received 4 mg reboxetine and placebo twice daily for periods of 14 days each with at least 14 days in between. Vasoconstrictory response of cutaneous vessels (VR) and skin conductance response (SCR) following sudden deep breath were employed as parameters for autonomic function. Quantitative EEG (qEEG) and psychometric tests served as parameters for cognitive function. Results: Reboxetine decreased SCR and prolonged the dilation phase of VR (P>0.05). It did not affect cognitive functions such as flicker fusion frequency, choice reaction, memory and psychomotor coordination but increased slow beta (beta1) power density in the qEEG. Tiredness (n = 12), dry mouth (n = 9), delayed urination (n = 3) and constipation (n = 1) were noted with reboxetine. Conclusion: Sustained peripheral and/or central sympathetic activation accounts for the prolongation of VR. The decrease of SCR and typical side effects suggest a relevant anti-muscarinic drug action. Chronic administration of reboxetine at therapeutic doses causes autonomic dysfunction and subjective sedation but does not impair cognitive and psychomotor abilities in healthy humans.

Original languageEnglish (US)
Pages (from-to)202-207
Number of pages6
JournalPsychopharmacology
Volume157
Issue number2
DOIs
StatePublished - 2001
Externally publishedYes

Fingerprint

Cognition
Healthy Volunteers
Autonomic Agents
Skin
Electroencephalography
Placebos
Flicker Fusion
Aptitude
Urination
Constipation
Double-Blind Method
Psychometrics
Cross-Over Studies
Cholinergic Agents
Epinephrine
Mouth
reboxetine
Dilatation
Pharmaceutical Preparations

Keywords

  • Autonomic function
  • Cognitive function
  • Reboxetine

ASJC Scopus subject areas

  • Pharmacology

Cite this

Chalasani, N., Clark, W. S., Martin, L. G., Kamean, J., Khan, M. A., Patel, N. H., & Boyer, T. D. (2001). The effects of reboxetine on autonomic and cognitive functions in healthy volunteers. Psychopharmacology, 157(2), 202-207. https://doi.org/10.1007/s002130100791

The effects of reboxetine on autonomic and cognitive functions in healthy volunteers. / Chalasani, Naga; Clark, W. Scott; Martin, L. G.; Kamean, Jeffrie; Khan, M. Abdul; Patel, Nilesh H.; Boyer, Thomas D.

In: Psychopharmacology, Vol. 157, No. 2, 2001, p. 202-207.

Research output: Contribution to journalArticle

Chalasani, N, Clark, WS, Martin, LG, Kamean, J, Khan, MA, Patel, NH & Boyer, TD 2001, 'The effects of reboxetine on autonomic and cognitive functions in healthy volunteers', Psychopharmacology, vol. 157, no. 2, pp. 202-207. https://doi.org/10.1007/s002130100791
Chalasani N, Clark WS, Martin LG, Kamean J, Khan MA, Patel NH et al. The effects of reboxetine on autonomic and cognitive functions in healthy volunteers. Psychopharmacology. 2001;157(2):202-207. https://doi.org/10.1007/s002130100791
Chalasani, Naga ; Clark, W. Scott ; Martin, L. G. ; Kamean, Jeffrie ; Khan, M. Abdul ; Patel, Nilesh H. ; Boyer, Thomas D. / The effects of reboxetine on autonomic and cognitive functions in healthy volunteers. In: Psychopharmacology. 2001 ; Vol. 157, No. 2. pp. 202-207.
@article{cd9369267d434f14ad41bc9fc0c0ceb8,
title = "The effects of reboxetine on autonomic and cognitive functions in healthy volunteers",
abstract = "Rationale: Though reboxetine, a selective nor-adrenaline reuptake inhibitor, causes autonomic and cognitive adverse events there is a paucity of appropriately designed studies on the cognitive and autonomic effects of the drug in the literature. Objective: To compare the effects of reboxetine on cognitive and autonomic functions with those of placebo in healthy humans. Method: A randomised, double-blind, crossover study of 12 healthy male volunteers aged 25 (21-27; median, range) years. Subjects orally received 4 mg reboxetine and placebo twice daily for periods of 14 days each with at least 14 days in between. Vasoconstrictory response of cutaneous vessels (VR) and skin conductance response (SCR) following sudden deep breath were employed as parameters for autonomic function. Quantitative EEG (qEEG) and psychometric tests served as parameters for cognitive function. Results: Reboxetine decreased SCR and prolonged the dilation phase of VR (P>0.05). It did not affect cognitive functions such as flicker fusion frequency, choice reaction, memory and psychomotor coordination but increased slow beta (beta1) power density in the qEEG. Tiredness (n = 12), dry mouth (n = 9), delayed urination (n = 3) and constipation (n = 1) were noted with reboxetine. Conclusion: Sustained peripheral and/or central sympathetic activation accounts for the prolongation of VR. The decrease of SCR and typical side effects suggest a relevant anti-muscarinic drug action. Chronic administration of reboxetine at therapeutic doses causes autonomic dysfunction and subjective sedation but does not impair cognitive and psychomotor abilities in healthy humans.",
keywords = "Autonomic function, Cognitive function, Reboxetine",
author = "Naga Chalasani and Clark, {W. Scott} and Martin, {L. G.} and Jeffrie Kamean and Khan, {M. Abdul} and Patel, {Nilesh H.} and Boyer, {Thomas D}",
year = "2001",
doi = "10.1007/s002130100791",
language = "English (US)",
volume = "157",
pages = "202--207",
journal = "Psychopharmacology",
issn = "0033-3158",
publisher = "Springer Verlag",
number = "2",

}

TY - JOUR

T1 - The effects of reboxetine on autonomic and cognitive functions in healthy volunteers

AU - Chalasani, Naga

AU - Clark, W. Scott

AU - Martin, L. G.

AU - Kamean, Jeffrie

AU - Khan, M. Abdul

AU - Patel, Nilesh H.

AU - Boyer, Thomas D

PY - 2001

Y1 - 2001

N2 - Rationale: Though reboxetine, a selective nor-adrenaline reuptake inhibitor, causes autonomic and cognitive adverse events there is a paucity of appropriately designed studies on the cognitive and autonomic effects of the drug in the literature. Objective: To compare the effects of reboxetine on cognitive and autonomic functions with those of placebo in healthy humans. Method: A randomised, double-blind, crossover study of 12 healthy male volunteers aged 25 (21-27; median, range) years. Subjects orally received 4 mg reboxetine and placebo twice daily for periods of 14 days each with at least 14 days in between. Vasoconstrictory response of cutaneous vessels (VR) and skin conductance response (SCR) following sudden deep breath were employed as parameters for autonomic function. Quantitative EEG (qEEG) and psychometric tests served as parameters for cognitive function. Results: Reboxetine decreased SCR and prolonged the dilation phase of VR (P>0.05). It did not affect cognitive functions such as flicker fusion frequency, choice reaction, memory and psychomotor coordination but increased slow beta (beta1) power density in the qEEG. Tiredness (n = 12), dry mouth (n = 9), delayed urination (n = 3) and constipation (n = 1) were noted with reboxetine. Conclusion: Sustained peripheral and/or central sympathetic activation accounts for the prolongation of VR. The decrease of SCR and typical side effects suggest a relevant anti-muscarinic drug action. Chronic administration of reboxetine at therapeutic doses causes autonomic dysfunction and subjective sedation but does not impair cognitive and psychomotor abilities in healthy humans.

AB - Rationale: Though reboxetine, a selective nor-adrenaline reuptake inhibitor, causes autonomic and cognitive adverse events there is a paucity of appropriately designed studies on the cognitive and autonomic effects of the drug in the literature. Objective: To compare the effects of reboxetine on cognitive and autonomic functions with those of placebo in healthy humans. Method: A randomised, double-blind, crossover study of 12 healthy male volunteers aged 25 (21-27; median, range) years. Subjects orally received 4 mg reboxetine and placebo twice daily for periods of 14 days each with at least 14 days in between. Vasoconstrictory response of cutaneous vessels (VR) and skin conductance response (SCR) following sudden deep breath were employed as parameters for autonomic function. Quantitative EEG (qEEG) and psychometric tests served as parameters for cognitive function. Results: Reboxetine decreased SCR and prolonged the dilation phase of VR (P>0.05). It did not affect cognitive functions such as flicker fusion frequency, choice reaction, memory and psychomotor coordination but increased slow beta (beta1) power density in the qEEG. Tiredness (n = 12), dry mouth (n = 9), delayed urination (n = 3) and constipation (n = 1) were noted with reboxetine. Conclusion: Sustained peripheral and/or central sympathetic activation accounts for the prolongation of VR. The decrease of SCR and typical side effects suggest a relevant anti-muscarinic drug action. Chronic administration of reboxetine at therapeutic doses causes autonomic dysfunction and subjective sedation but does not impair cognitive and psychomotor abilities in healthy humans.

KW - Autonomic function

KW - Cognitive function

KW - Reboxetine

UR - http://www.scopus.com/inward/record.url?scp=0034877174&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034877174&partnerID=8YFLogxK

U2 - 10.1007/s002130100791

DO - 10.1007/s002130100791

M3 - Article

C2 - 11594447

AN - SCOPUS:0034877174

VL - 157

SP - 202

EP - 207

JO - Psychopharmacology

JF - Psychopharmacology

SN - 0033-3158

IS - 2

ER -